Summary

A key advisory committee that reviews medical devices for the Food and Drug Administration will meet today to vote on whether the agency should approve the first multi-cancer blood test. Grail, the company that makes the Galleri blood test under review, says it can detect up to 50 forms of cancer, many of which are not routinely screened for today. The panel of independent experts will hear from Grail, FDA officials and the public before voting on a recommendation.

AI summaries can be wrong sometimes—always verify important details using the source article.